News
Market and company headlines
LLYAll
Loading
08:00Yesterday1 Story
18:00-21:00Oct 252 Stories
Eli Lilly Stock Fell 2.5% Ahead of Q3. Here’s Why Revenue Could Dip Even as Patients Grow
Key Stats for Eli Lilly StockCurrent Price: $1,273. 46Target Price (Mid): ~$2,220Street Target: ~$1,330Potential Total Return: ~74%Annualized IRR: ~14% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?Eli Lilly (LLY) closed at $1,273.
Eli Lilly (LLY) Reports Strong Phase 1 Ovarian Cancer Data
Eli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients. The regimen showed a high confirmed response rate and disease control rate in both PARP inhibitor-experienced and naïve groups. Investigators observed consistent benefit across different FRa expression levels with no major new safety signals reported for Sofe-M. The Sofe-M and bevacizumab Phase 1 results in ovarian cancer are a fresh factor to weigh against our broader...
11:00Oct 251 Story
07:00Oct 241 Story
15:00-22:00Oct 232 Stories
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst performers in the branded pharmaceuticals industry.
Goldman Sachs resets Eli Lilly 12-month stock price target before earnings
Wall Street expects strong numbers from LLY, but Goldman says one figure will decide the reaction.
14:00Oct 232 Stories
Eli Lilly Gained 10% in a Week to a New 52-Week High. Is There Room to Run?
Key TakeawaysEli Lilly stock rose 10% in the week through Tuesday’s close to a record, while the S&P 500 fell 1. 1% and the Nasdaq 100 fell 3.
Eli Lilly (LLY) Builds In Richmond As Fair Value Still Sits Higher
Eli Lilly (LLY) just put a shovel in the ground on a new US$5b manufacturing hub near Richmond, Virginia, a fully integrated site for active ingredients and finished antibody drug conjugate medicines. Eli Lilly shares have been on a strong run, with a 30 day share price return of 11.67% and a year to date share price gain of 20.95%. The 1 year total shareholder return of 60.15% and 5 year total shareholder return of 439.71% point to powerful longer term momentum that recent drug data,...
08:00-12:00Oct 232 Stories
Polen Focus Growth Strategy Trims Eli Lilly and Company (LLY) While Maintaining Confidence in Its Outlook
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” Q3 2026 investor letter. A copy of the letter can be downloaded here. The fund outperformed the Russell 1000 Growth Index in the third quarter of 2026, as investors began distinguishing between businesses vulnerable to artificial intelligence disruption and those positioned to benefit […]
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader
Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.
07:00-10:00Oct 222 Stories
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.
12:00-14:00Oct 212 Stories
Eli Lilly (LLY) Grew Revenue 48% While Prices Fell, Can Volume Keep Winning?
Eli Lilly (NYSE:LLY) reports third-quarter results in about a week, and the split between volume and price matters more than the headline total. In the second quarter, revenue rose 48% to $23.0 billion on a 60% jump in the amount of medicine sold, while the price Lilly collected per unit fell 13%. The company is […]
If You Invested $100 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.86% on an annualized basis producing an average annual return of 16.86%. Currently, Eli Lilly has a market capitalization of $1.11 trillion.
09:00Oct 212 Stories
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316
Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1309 to $1316.
LLY Stock Alert: What to Know as Eli Lilly Hits a New All-Time High
Eli Lilly stock printed a new all-time high yesterday. Here’s what has driven LLY shares higher and what comes next.
08:00Oct 211 Story
12:00-14:00Oct 204 Stories
Is Pediatric Ulcerative Colitis Data Altering The Investment Case For Lilly (LLY)?
Eli Lilly reported one year Phase 3 SHINE-2 data showing Omvoh achieved its primary endpoint in pediatric ulcerative colitis, with 50% of Week 12 responders aged 6 to 17 in clinical remission at Week 52 and a safety profile consistent with adults. The trial enrolled a high burden group, including many children with prior biologic treatment failure. This points to a potentially meaningful extension of Eli Lilly’s inflammatory bowel disease franchise if regulators eventually approve a...
LLY Stock Hits New Record, Eli Lilly Valuation Pushes Past Berkshire Hathaway Ahead Of Q3 Earnings
According to The Fly, Goldman Sachs expects Lilly to beat Q3 earnings estimates and raise its outlook, citing stronger-than-expected Mounjaro growth outside the U.S. and Zepbound volume gains supported by Medicare’s GLP-1 Bridge program.
11:00Oct 202 Stories
How to Trade Eli Lilly Stock at New All-Time Highs
Eli Lilly (LLY) exhibits exceptional growth, profitability, and momentum, reaching a new all-time high today. Shares are up more than 60% over the past year. LLY maintains a 100% “Buy” technical opinion from Barchart. I recommend maintaining a rational stop loss given the stock’s momentum and volatility, despite continued analyst...
If Eli Lilly Grows At 10% a Year, Here’s What $1,000 Becomes By 2030
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook.
07:00Oct 201 Story
14:00-17:00Oct 192 Stories
12:00Oct 192 Stories
Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds.
Why Is Eli Lilly (LLY) Being Sued Over Alleged Insulin Price Inflation?
Eli Lilly (NYSE:LLY) faces a new Pennsylvania lawsuit alleging drugmakers inflated insulin prices by over 1,000%. The complaint, filed on behalf of state consumers, targets Eli Lilly and other large insulin manufacturers and pharmacy benefit managers. Plaintiffs argue the alleged pricing scheme significantly increased out of pocket insulin costs for patients in Pennsylvania. This alleged 1,000% insulin price inflation is only one piece of the wider Eli Lilly story investors are assessing...
10:00Oct 192 Stories
Eli Lilly's Foundayo to Keep Gaining Market Share Over Next 12 Months, BofA Says
Eli Lilly's (LLY) Foundayo, its oral GLP-1 treatment, is expected to keep gaining share over the nex
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Is this company the biggest dark horse in the chronic weight management space?
09:00Oct 192 Stories
Eli Lilly Signs Up to $1.1 Billion Metis Deal: Here’s What It’s Really Worth
Eli Lilly (LLY:NYSE) has signed a research collaboration with Hong Kong-listed Metis TechBio (7666. HK:HKSE) that Reuters reported on Monday, October 19, is worth up to $1.
Can Eli Lilly’s Growth Keep Justifying its Premium?
Eli Lilly and Company (NYSE:LLY) has delivered the kind of growth that helps explain why investors are willing to pay a premium for its shares. The stock has returned over 55% in the past 12 months, compared with a nearly 14% growth of the S&P 500. That multiple reflects substantial expectations for future profitability. With […]
07:00Oct 191 Story
10:00-19:00Oct 182 Stories
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. Highlights include new Phase 1 data in platinum-sensitive ovarian cancer (PSOC) for sofetabart mipitecan (Sofe-M), Lilly's investigational FRα-targeting antibody-drug conjugate (ADC), in combination with bevacizumab, along with updated findings for olomorasib, Retevmo (selper
Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?
Eli Lilly and Company (NYSE:LLY) has returned 36.37% over the last six months, as of October 15. This compares to a 21.5% return for the Insider Monkey Billionaire Index and 15.74% for the State Street SPDR S&P 500 ETF Trust. Eli Lilly is no longer just a pharmaceutical company benefiting from the popularity of weight-loss […]
09:00Oct 181 Story
10:00Oct 171 Story
14:00-23:00Oct 163 Stories
What Was Eli Lilly Telling You Before Its Stock Ran?
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.
A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
12:00Oct 162 Stories
Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO
The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of
Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
Eli Lilly and Company (NYSE:LLY) has become one of the pharmaceutical industry’s most important growth stories, but its valuation presents a harder question than whether demand for obesity treatments will continue to rise. Investors must decide how much of that growth remains ahead, and how much is already reflected in the share price. Lilly’s shares […]
11:00Oct 163 Stories
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A new government-funded study found that GLP-1 drugs slow the aging process in mice.
Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months
European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Novo Nordisk S/A (NYSE:NVO)’s investment story has changed dramatically. The stock has declined by over 25% since the start of 2026. The selloff has changed the stock’s valuation. Yahoo Finance’s latest data puts Novo Nordisk at 11.83 times forward earnings, compared with 13.33 in September 2025. That makes Novo look considerably less demanding than it […]
03:00-08:00Oct 162 Stories
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
The Lilly Foundation is unloading 300,000 shares of the stock.
Eli Lilly Receives EMA CHMP Positive Opinion Recommending Marketing Authorization For Foundayo For Treatment Of Type 2 Diabetes Mellitus And For Weight Management
https://www.ema.europa.eu/en/medicines/human/EPAR/foundayo
07:00-13:00Oct 142 Stories
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
Eli Lilly and Company Earnings Preview: What to Expect
Eli Lilly and Company is set to report its Q3 results soon, with analysts anticipating single-digit EPS growth alongside continued earnings growth.
17:00Oct 132 Stories
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.
How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story
Eli Lilly recently reported exploratory Phase 3b data from the TOGETHER-PsO trial showing that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight altered far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings highlight a potential immunometabolic link between psoriasis and obesity, suggesting Lilly could unlock new treatment approaches by pairing its immunology and...
15:00-17:00Oct 132 Stories
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.
10:00-13:00Oct 132 Stories
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.
Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.
Eli Lilly's next big growth driver could be bigger than Zepbound.
09:00-20:00Oct 42 Stories
Eli Lilly’s Valuation Has Changed. Here’s What Investors Need to Know
Eli Lilly and Company (NYSE:LLY) has carved out a strong position in the pharmaceutical industry, with much of its competitive advantage now tied to its leadership in diabetes and obesity treatments. The company’s moat comes from several factors working together: drug innovation, patent protection, manufacturing capacity, brand strength, and a deep pipeline of new treatments. […]
Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet
Can anyone stop Eli Lilly’s progress in the weight loss market?